Van ECK Associates Corp increased its stake in shares of Sanofi (NASDAQ:SNY - Free Report) by 18.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 662,762 shares of the company's stock after buying an additional 101,726 shares during the period. Van ECK Associates Corp's holdings in Sanofi were worth $31,965,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also added to or reduced their stakes in SNY. Jennison Associates LLC raised its holdings in Sanofi by 938.0% during the 3rd quarter. Jennison Associates LLC now owns 1,904,445 shares of the company's stock worth $109,753,000 after purchasing an additional 1,720,972 shares during the last quarter. Thrivent Financial for Lutherans increased its stake in shares of Sanofi by 28,890.2% in the 3rd quarter. Thrivent Financial for Lutherans now owns 1,429,219 shares of the company's stock valued at $82,366,000 after acquiring an additional 1,424,289 shares during the last quarter. DAVENPORT & Co LLC increased its stake in shares of Sanofi by 40.7% in the 4th quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company's stock valued at $110,715,000 after acquiring an additional 664,455 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Sanofi by 20.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company's stock valued at $133,172,000 after acquiring an additional 399,301 shares during the last quarter. Finally, Franklin Resources Inc. increased its stake in shares of Sanofi by 13.1% in the 3rd quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company's stock valued at $208,106,000 after acquiring an additional 395,744 shares during the last quarter. Institutional investors and hedge funds own 14.04% of the company's stock.
Sanofi Stock Down 1.0 %
Shares of SNY traded down $0.56 on Tuesday, hitting $53.95. The company's stock had a trading volume of 1,210,703 shares, compared to its average volume of 2,475,394. The company has a quick ratio of 0.74, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The firm's fifty day moving average price is $50.42 and its 200-day moving average price is $52.47. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $58.97. The firm has a market capitalization of $136.90 billion, a price-to-earnings ratio of 21.66, a P/E/G ratio of 0.99 and a beta of 0.57.
Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.70. Sanofi had a return on equity of 25.58% and a net margin of 12.77%. On average, equities research analysts expect that Sanofi will post 4.36 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of analysts have recently commented on the company. StockNews.com cut Sanofi from a "buy" rating to a "hold" rating in a research note on Thursday, December 12th. Sanford C. Bernstein raised Sanofi to a "strong-buy" rating in a research note on Thursday, January 30th. Finally, Deutsche Bank Aktiengesellschaft raised Sanofi from a "sell" rating to a "hold" rating in a research note on Thursday, January 30th. Two investment analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $60.00.
Check Out Our Latest Report on SNY
About Sanofi
(
Free Report)
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Featured Stories
Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
